Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.6 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Cempra Completes Patient Enrollment of Solitaire-IV Phase 3 Clinical Trial

July 7, 2015
CHAPEL HILL, N.C., July 7, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial…
READ MORE

Esperion Therapeutics Announces Removal of 240 mg Partial Clinical Hold for ETC - 1002

July 7, 2015
ANN ARBOR, MI -- (Marketwired) -- 07/07/15 -- Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies…
READ MORE

Advion Acquired by Bejing Bohui Innovation Technology, Inc.

July 1, 2015
July 1, 2015 – Ithaca, NY – As previously mentioned in the June 5, 2015 announcement of the signing of the Merger Agreement, effective July 1, 2015, Beijing Bohui Innovation…
READ MORE